Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 97

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 97
---
 on our rights under the
option agreement.

We intend to evaluate the results of a
planned large-animal study—originally expected in the fourth quarter of 2025 and now anticipated in the first half of
2026—before determining whether to exercise the exclusive license option. Initiation of this study has been delayed pending
receipt of what we consider to be the contractually required final scientific report. If we are unable to obtain the exclusive
license to the ARB program or determine not to pursue it, the Nano-Candesartan program would no longer be part of our development
pipeline. In such circumstances, we may be required to reassess the carrying value of intangible assets associated with the ARB
program. Notwithstanding the need for further agreement on these matters, we present below our current understanding of the
development efforts, pre-clinical studies and potential market opportunities relating to the Nano-Candesartan product
candidate.

The Company’s next drug candidate is another
novel nanoparticles-based formulation of angiotensin receptor blockers (ARBs), also known as AT1 receptor blockers (AT1) for intravenous
(IV) administration – Nano-Candesartan.

The Company holds an exclusive option to obtain
an exclusive, worldwide license for the development, manufacturing, and commercialization of products incorporating the technology underlying
the novel liposomal Angiotensin Receptor Blocker (ARB) formulation. The option must be exercised within 90 days following receipt of
the final scientific report, after which the parties have up to 120 days to negotiate the definitive licensing agreement. As part of
this process, the Company plans to conduct large animal safety studies in the fourth quarter of 2025 to support its decision on whether
to exercise the licensing option and finalize the related terms. If results do not meet established thresholds, we do not intend to exercise
the option. If no agreement is reached within the negotiation period, Yissum shall have no further obligations to the Company with respect
to the technology.

ARBs is a class of drugs that block the Angiotensin
II Type 1 receptor (AT1), which is involved in the regulation of blood pressure, fluid balance, and inflammation. ARBs have been widely
used for the treatment of hypertension, heart failure, and diabetic nephropathy. Several recent studies have shown that ARBs may have
certain anti-cancer enhancement features. Among other, ARBs can inhibit proliferation, migration, invasion, and angiogenesis of